Method and system for managing hemodynamic state and oxygen transport

• US 5,551,435 A
• Filed: 05/26/1995
• Issued: 09/03/1996
• Est. Priority Date: 05/26/1995
• Status: Expired due to Term

• Current Assignee: Hemo Sapiens, Inc.
• Original Assignee: Bohumir Sramek
• Inventors: Sramek, Bohumir
• Primary Examiner(s): Sykes, Angela D.
• Assistant Examiner(s): NASSER, ROBERT L
• Application Number:
  US08/452,271
• Time in Patent Office: 466 Days
• Field of Search: 128/668, 128/672, 128/677, 128/680-3, 128/691-694, 128/713, 128/734, 604/50, 604/65-67
• US Class Current: 600/481
• CPC Class Codes: A61B 5/02007 Evaluating blood vessel condition, e.g. elasticity, compliance
• CPC Class Codes: A61B 5/02028 Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
• CPC Class Codes: A61B 5/0205 Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• CPC Class Codes: A61B 5/021 Measuring pressure in heart or blood vessels A61B5/0205 takes precedence
• CPC Class Codes: A61B 5/024 Detecting, measuring or recording pulse rate or heart rate A61B5/0205, A61B5/021 take precedence
• CPC Class Codes: A61B 5/029 Measuring or recording blood output from the heart, e.g. minute volume A61B8/065 takes precedence
• CPC Class Codes: A61B 5/053 Measuring electrical impedance or conductance of a portion of the body
• CPC Class Codes: A61B 5/14551 for measuring blood gases
• CPC Class Codes: A61B 5/4839 combined with drug delivery

Abstract

A method of attaining a preselected systemic hemodynamic state in an patient using a per-beat basis, such as for example paired values of MAP and SI, rather than a per-minute basis, such as MAP and CI. A method of utilizing Hemodynamic Management Charts (HMCs) which permits the integration of data concerning systemic hemodynamic modulators and the systemic hemodynamic state, and which allows the identification of deviations in the levels of the hemodynamic modulators from normal levels. Also, a computer-based system which measures hemodynamic parameters and implements at least one HMC into its software, thereby permitting identification of deviations in the levels of hemodynamic modulators from normal levels. Therapeutic corrections of the deviations in hemodynamic modulator levels, such as through pharmacologically active agents or volume expanders, based on the foundation and HMCs enables the clinician to establish and maintain a patient in the normal hemodynamic state and normal perfusion state.

Claims

1. A method of attaining a preselected combination of MAP, SI and CI in patient comprising the steps of:

(a) determining the patient'"'"'s mean arterial pressure (MAP), stroke index (SI) and cardiac index (CI);

(b) determining the deviation from ideal of the patient'"'"'s hemodynamic modulators intravascular volume, inotropy, chronotropy and vasoactivity using the MAP, SI and CI determined in step (a);

(c) preselecting a desired combination of MAP, SI and CI; and

(d) administering therapeutic doses of one or more pharmacologically active agents or volume expanders for altering one or more of the hemodynamic modulators to attain the preselected combination of MAP, SI and CI.

2. The method of claim 1, wherein the patient is selected from a subgroup of patients consisting of neonates, children, adult males, non-pregnant women of child bearing age, pregnant women, elderly men and elderly women.

3. The method of claim 1, wherein the one or more pharmacologically active agents or volume expanders is selected from the group consisting of a positive inotrope, a negative inotrope, a vasoconstrictor, a vasodilator, a diuretic, a positive chronotrope and a negative chronotrope.

4. The method of claim 1, wherein the preselected combination of MAP, SI and CI is a MAP between about 70-105 Torr, SI between about 35-65 ml/m² and CI between 2.8 and 4.2 l/m/m².

5. A method of attaining a preselected combination of MAP, SI and CI in patient comprising the steps of:

(a) determining the patient'"'"'s mean arterial pressure (MAP), stroke index (SI) and cardiac index (CI);

(b) preselecting a desired combination of MAP, SI and CI; and

(c) administering therapeutic doses of one or more pharmacologically active agents or volume expanders for altering the patient'"'"'s MAP, heart rate (HR) or SI to attain the preselected combination of MAP, SI and CI.

6. The method of claim 5, wherein the patient is selected from a subgroup of patients consisting of neonates, children, adult males, non-pregnant women of child bearing age, pregnant women, elderly men and elderly women.

7. The method of claim 5, wherein the one or more pharmacologically active agents or volume expanders is selected from the group consisting of a positive inotrope, a negative inotrope, a vasoconstrictor, a vasodilator, a diuretic, a positive chronutrope and a negative chronotrope.

8. The method of claim 5, wherein the preselected combination of MAP, SI and CI is a MAP between about 70-105 Torr, SI between about 35-65 ml/m² and CI between 2.8 and 4.2 l/m/m².

9. A method of attaining a preselected combination of MAP, SI and CI, or a preselected combination of LSWI and SSVRI in patient comprising the steps of:

(a) determining the patient'"'"'s mean arterial pressure (MAP), stroke index (SI) and cardiac index (CI);

(b) determining the patient'"'"'s left stroke work index (LSWI) according to formula;

space="preserve" listing-type="equation">LSWI=A×

{SI×

(MAP-LAP)}

and determining the patient'"'"'s stroke systemic vascular resistance index (SSVRI) according to the formula;

space="preserve" listing-type="equation">SSVRI=B×

(MAP-CVP)/SI

where LAP represents left atrial pressure, CVP represents central venous pressure and A and B are constants;

(c) determining the patient'"'"'s deviation of the combined hemodynamic modulators {volume±

inotropy}, d{V±

I}, from normovolemia/normoinotropy according to the formula;

space="preserve" listing-type="equation">d{V±

I}=+(LSWI.sub.actual /LSWI.sub.ideal -1)×

100

when LSWI_actual >

LSWI_ideal or from the formula;

space="preserve" listing-type="equation">d{V±

I}=-(LSWI.sub.ideal /LSWI.sub.actual -1)×

100

when LSWI_actual <

LSWI_ideal, where LSWI_actual is the LSWI determined in step (b) and LSWI_ideal is known from predetermined values according to the type of patient and clinical state;

(d) determining the patient'"'"'s Inotropic State Index (ISI)

(e) determining the patient'"'"'s deviation in inotropy (dI) from normoinotropy using the formula;

space="preserve" listing-type="equation">dI=+(ISI.sub.ideal /ISI.sub.ideal -1)×

100

when ISI_actual >

ISI_ideal or from the formula;

space="preserve" listing-type="equation">dI=-(ISI.sub.ideal /ISI.sub.actual -1)×

100

when ISI_actual <

ISI_ideal, where ISI_actual is the ISI determined in step (d) and ISI_ideal is known from predetermined values according to the type of patient and clinical state;

(f) determining the patient'"'"'s deviation in volemia, dV, from normovolenta using the formula;

space="preserve" listing-type="equation">dV=d{V±

I}±

dI

(g) determining the patient'"'"'s deviation in vasoactivity, d(Vaso), from normovasoactivity using the formula;

space="preserve" listing-type="equation">d(Vaso)=+(SSVRI.sub.actual /SSVRI.sub.ideal -1)×

100

when SSVRI_actual >

SSVRI_ideal, and from the formula;

space="preserve" listing-type="equation">d(Vaso)=-(SSVRI.sub.ideal /SSVRI.sub.actual -1)×

100

when SSVRI_actual <

SSVRI_ideal, where SSVRI_actual is the SSVRI determined in step (b) and SSVRI_ideal is known from predetermined values according to the type of patient and clinical state;

(h) determining the patient'"'"'s deviation in chronotropy (dC), from normochronotropy using the formula;

space="preserve" listing-type="equation">dC=+(CI.sub.actual /CI.sub.ideal -1)×

100

when CI_actual >

CI_ideal, and from the formula;

space="preserve" listing-type="equation">dC=-(CI.sub.ideal /CI.sub.actual -1)×

100

when CI_actual <

CI_ideal, where CI_actual is the CI determined in step (a) and CI_ideal is known from predetermined values according to the type of patient and clinical state;

(i) preselecting a desired combination of MAP, SI and CI, or a desired combination of LSWI and SSVRI; and

(j) administering therapeutic doses of one or more pharmacologically active agents or volume expanders for altering one or more hemodynamic modulators to attain the preselected combination of step (i).

10. The method of claim 9, wherein the patient is selected from a subgroup of patients consisting of neonates, children, adult males, non-pregnant women of child bearing age, pregnant women, elderly men and elderly women.

11. The method or claim 9, wherein the one or more pharmacologically active agents or volume expanders is selected from the group consisting of a positive inotrope, a negative inotrope, a vasoconstrictor, a vasodilator, a diuretic, a positive chronotrope and a negative chronotrope.

12. The method of claim 9, wherein the preselected combination of MAP, SI and CI is a MAP between about 70-105 Torr, SI between about 35-65 ml/m² and CI between 2.8 and 4.2 l/m/m².

13. The method of claim 9, wherein the preselected combination of LSWI and SSVRI is a LSWI between about 39.3-73.0 g.m/m² and an SSVRI between about 99,692-185,142 dyn.sec.cm^-5.m².